A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 781

H Hirte, S Lheureux, G F Fleming, A Sugimoto, R Morgan, J Biagi, L Wang, S McGill, S P Ivy, A M Oza. Gynecol Oncol 2015
Times Cited: 37

List of shared articles

Times cited

Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Vinaya Gogineni, Susan Morand, Hannah Staats, Rachel Royfman, Monika Devanaboyina, Katelyn Einloth, Danielle Dever, Laura Stanbery, Phylicia Aaron, Luisa Manning,[...]. J Cancer 2021

Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
Virginie Mieulet, Camille Garnier, Yann Kieffer, Thomas Guilbert, Fariba Nemati, Elisabetta Marangoni, Gilles Renault, Foucauld Chamming's, Anne Vincent-Salomon, Fatima Mechta-Grigoriou. Sci Rep 2021

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021

Recent advancements of antiangiogenic combination therapies in ovarian cancer.
Daniel An, Susana Banerjee, Jung-Min Lee. Cancer Treat Rev 2021

Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui, Liying Han. Curr Drug Targets 2020